Measures · D10 in 2023 · Part D · DD4 Drug Safety and Accuracy of Drug Pricing
Medication Adherence for Cholesterol (Statins)
Drug PlanMedication AdherenceSource: Prescription Drug Events
- What it measures
- Percent of plan members with a prescription for a cholesterol medication (a statin drug) who fill their prescription often enough to cover 80% or more of the time they are supposed to be taking the medication. One of the most important ways people with high cholesterol can manage their health is by taking medication as directed. The plan, the doctor, and the member can work together to do this.
- How it's calculated
- This measure is defined as the percent of Medicare Part D beneficiaries 18 years and older who adhere to their prescribed drug therapy for statin cholesterol medications. This percentage is calculated as the number of member-years of enrolled beneficiaries 18 years and older with a proportion of days covered (PDC) at 80 percent or higher for statin cholesterol medication(s) during the measurement period (numerator) divided by the number of member-years of enrolled beneficiaries 18 years and older with at least two statin cholesterol medication fills on unique dates of service during the measurement period (denominator). The PDC is the percent of days in the measurement period “covered” by prescription claims for the same medication or another in the therapeutic category. Beneficiaries are only included in the measure calculation if the first fill of their statin medication occurs at least 91 days before the end of the enrollment period. The Medication Adherence measure is adapted from the Medication Adherence- Proportion of Days Covered measure that was developed and endorsed by the Pharmacy Quality Alliance (PQA). See the medication list for this measure. The Medication Adherence rate is calculated using the National Drug Code (NDC) list maintained by the PQA. The complete NDC list, including diagnosis codes, is posted along with these technical notes.
- Data source
- Prescription Drug Event (PDE) data The data for this measure come from PDE data submitted by drug plans to the CMS Drug Data Processing Systems (DDPS) and accepted by the 2021 PDE submission deadline for annual Part D payment reconciliation with dates of service from January 1, 2021-December 31, 2021. If the PDE edit results in the PDE being rejected by DDPS, then the PDE is not used in the Patient Safety measure calculations. If the PDE edit is informational and therefore, does not result in the PDE being rejected, then the PDE is used in the Patient Safety measure calculations. Reminder, CMS uses the term “final action” PDE to describe the most recently accepted original, adjustment, or deleted PDE record representing a single dispensing event. Original and adjustment final action PDEs submitted by the sponsor and accepted by DDPS prior to the 2021 PDE submission deadline are used to calculate this measure. PDE claims are limited to members who received at least two prescriptions on unique dates of service for statin medication. PDE adjustments made post-reconciliation were not reflected in this measure. Additional data sources include the Common Medicare Environment (CME), the Medicare Enrollment Database (EDB), the Common Working File (CWF), the Encounter Data Systems (EDS), and the Risk Adjustment Processing System (RAPS). • CME is used for enrollment information. • EDB is used for hospice enrollment and ESRD status (dialysis start and end dates within the measurement period). • CWF is used to identify exclusion diagnoses based on ICD-10-CM codes, inpatient (IP) and skilled nursing facility (SNF) stays for PDPs and MA-PDs (if available). • EDS is used to identify diagnoses based on ICD-10-CM codes, and SNF/IP stays for MA-PD beneficiaries. • RAPS is used for diagnosis information, RxHCC - Dialysis Status (most recent available Payment Year).
- Measurement period
- 01/01/2021 – 12/31/2021
- Better when
- Higher
- Weight
- 3 (Intermediate Outcome Measure)
- Star assignment
- Clustering
- Case-mix adjusted
- No
- In improvement measure
- Yes
- Used in CAI
- Yes
- Exclusions
Show
Contracts with 30 or fewer enrolled member-years (in the denominator). The following beneficiaries are also excluded from the denominator if at any time during the measurement period: • Hospice enrollment • ESRD diagnosis or dialysis coverage dates- Notes
- Part D drugs do not include drugs or classes of drugs, or their medical uses, which may be excluded from coverage or otherwise restricted under section 1927(d)(2) of the Act, except for smoking cessation agents. As such, these drugs, which may be included in the PQA medication or NDC lists, are excluded from CMS analyses. Also, the member- years of enrollment adjustment is made by CMS to account for partial enrollment within the benefit year. Enrollment is measured at the episode level, and inclusion in the measure is determined separately for each episode – i.e., to be included for a given episode, the beneficiary must meet the initial inclusion criteria for the measure during that episode. The measure is weighted based on the total number of member-years for each enrollment episode in which the beneficiary meets the measure criteria. For instance, if a beneficiary is enrolled for a three-month episode, disenrolled for a six-month episode, reenrolled for a three-month episode, and meets the measure criteria during each enrollment episode, s/he will count as 0.5 member years in the rate calculation (3/12 + 3/12 = 6/12). The PDC calculation is adjusted for overlapping prescriptions for the same drug which is defined by active ingredient at the generic name level using the NDC list maintained by PQA. The calculation also adjusts for Part D beneficiaries’ stays in inpatient (IP) settings, and stays in skilled nursing facilities (SNFs). The discharge date is included as an adjustment day for IP/SNF stays. Please see Attachment K: Medication Adherence Measure Calculations for more information about these calculation adjustments. When available, beneficiary death date from the CME is the end date of a beneficiary’s measurement period.
- Disaster policy
- Higher measure star (2022-2023) for contracts with 25% or more enrolled affected by 2021 disasters.
From the 2023 Star Ratings Technical Notes (CMS).
Cut points over time
Score needed to earn each star level. Part D thresholds differ for MA-PD and standalone PDP contracts. Dotted lines and open dots: where the cut points may move for 2028.
How the 2028 cut points are projected
Each boundary moves by its median year-on-year change since 2019, capped at 5 points, the most CMS lets a non-survey cut point move in a year. It's the same projection the Star outlook uses for every contract. CMS sets real cut points from all contracts' scores each year, so treat these as a direction, not a forecast of the exact number.
| Stars | Org type | 2027 | Projected 2028 | Move |
|---|---|---|---|---|
| 2★ | MA-PD | 84 | 87 | +3 |
| 3★ | MA-PD | 88 | 89 | +1 |
| 4★ | MA-PD | 90 | 91 | +1 |
| 5★ | MA-PD | 93 | 94 | +1 |
| 2★ | PDP | 86 | 87 | +1 |
| 3★ | PDP | 88 | 89 | +1 |
| 4★ | PDP | 90 | 91 | +1 |
| 5★ | PDP | 93 | 93 | 0 |
2023 star distribution
Not rated: Plan too new to be measured (130); Not enough data available (37); No data available (28); Plan not required to report measure (6)
Cut point bands
| Star year | Org type | 1★ | 2★ | 3★ | 4★ | 5★ |
|---|---|---|---|---|---|---|
| 2027 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2027 | PDP | < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2026 | MA-PD | < 84 % | >= 84 % to < 88 % | >= 88 % to < 90 % | >= 90 % to < 93 % | >= 93 % |
| 2026 | PDP | < 87 % | >= 87 % to < 89 % | >= 89 % to < 90 % | >= 90 % to < 92 % | >= 92 % |
| 2025 | MA-PD | < 80 % | >= 80 % to < 85 % | >= 85 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2025 | PDP | < 86 % | >= 86 % to < 88 % | >= 88 % to < 89 % | >= 89 % to < 92 % | >= 92 % |
| 2024 | MA-PD | < 82 % | >= 82 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 91 % | >= 91 % |
| 2024 | PDP | < 84 % | >= 84 % to < 87 % | >= 87 % to < 89 % | >= 89 % to < 93 % | >= 93 % |
| 2023 | MA-PD | < 81 % | >= 81 % to < 85 % | >= 85 % to < 88 % | >= 88 % to < 92 % | >= 92 % |
| 2023 | PDP | < 84 % | >= 84 % to < 87 % | >= 87 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2022 | MA-PD | < 78 % | >= 78 % to < 83 % | >= 83 % to < 87 % | >= 87 % to < 91 % | >= 91 % |
| 2022 | PDP | < 82 % | >= 82 % to < 86 % | >= 86 % to < 88 % | >= 88 % to < 90 % | >= 90 % |
| 2021 | MA-PD | < 75 % | >= 75 % to < 83 % | >= 83 % to < 86 % | >= 86 % to < 88 % | >= 88 % |
| 2021 | PDP | < 78 % | >= 78 % to < 81 % | >= 81 % to < 86 % | >= 86 % to < 88 % | >= 88 % |
| 2020 | MA-PD | < 72% | ? 72% to < 80% | ? 80% to < 84% | ? 84% to < 87% | ? 87% |
| 2020 | PDP | < 79% | ? 79% to < 83% | ? 83% to < 86% | ? 86% to < 88% | ? 88% |
| 2019 | MA-PD | < 73% | ? 73% to < 77% | ? 77% to < 83% | ? 83% to < 87% | ? 87% |
| 2019 | PDP | < 80% | ? 80% to < 82% | ? 82% to < 84% | ? 84% to < 88% | ? 88% |
| 2018 | MA-PD | < 66% | ? 66% to < 76% | ? 76% to < 80% | ? 80% to < 85% | ? 85% |
| 2018 | PDP | < 73% | ? 73% to < 79% | ? 79% to < 82% | ? 82% to < 86% | ? 86% |
| 2017 | MA-PD | < 66% | ? 66% to < 73% | ? 73% to < 77% | ? 77% to < 82% | ? 82% |
| 2017 | PDP | < 70% | ? 70% to < 74% | ? 74% to < 80% | ? 80% to < 84% | ? 84% |
| 2016 | MA-PD | < 50% | ? 50% to < 61% | ? 61% to < 73% | ? 73% to < 79% | ? 79% |
| 2016 | PDP | < 68% | ? 68% to < 73% | ? 73% to < 78% | ? 78% to < 83% | ? 83% |
| 2015 | MA-PD | < 59% | ? 59% to < 68% | ? 68% to < 76% | ? 76% to < 83% | ? 83% |
| 2015 | PDP | < 62% | ? 62% to < 69% | ? 69% to < 75% | ? 75% to < 78% | ? 78% |
Lowest-scoring contracts, 2023
| Contract | Parent | Members | Score | Stars | Δ | Shortfall to 4★ | Pctile |
|---|---|---|---|---|---|---|---|
| S2874 Humana | Humana Inc. | — | 74 | 1 | 0 | 14 | 0% |
| H6672 Clear Spring Health | Group 1001 | — | 69 | 1 | −1 | 19 | 0% |
| H3015 Shared Health Dual Plus - DE H3015-001 (HMO D-SNP) | BlueCross BlueShield of Tennessee | — | 72 | 1 | — | 16 | 0% |
| H1644 Longevity Health Plan | Longevity Health Founders, LLC | 804 | 73 | 1 | 0 | 15 | 0% |
| H8457 Longevity Health Plan | Longevity Health Founders, LLC | 701 | 73 | 1 | −1 | 15 | 0% |
| H1947 Healthy Blue | Elevance Health, Inc. | 3,486 | 74 | 1 | 0 | 14 | 1% |
| H1848 Wellcare | Centene Corporation | — | 74 | 1 | — | 14 | 1% |
| H0482 Wellcare by Allwell | Centene Corporation | — | 75 | 1 | — | 13 | 1% |
| H7522 Medicare y Mucho Mas (MMM) | Elevance Health, Inc. | 0 | 76 | 1 | 0 | 12 | 1% |
| H5454 Clear Spring Health | Group 1001 | — | 76 | 1 | — | 12 | 1% |
| H3047 Wellcare | Centene Corporation | — | 76 | 1 | — | 12 | 1% |
| H9861 CCA Health Michigan | Commonwealth Care Alliance, Inc. | — | 76 | 1 | −1 | 12 | 1% |
| H8854 CareFirst BlueCross BlueShield Advantage DualPrime | CareFirst, Inc. | 8,599 | 76 | 1 | −1 | 12 | 1% |
| H8010 Clover Health | Clover Health Holdings, Inc. | 3,862 | 77 | 1 | −1 | 11 | 2% |
| H5374 Longevity Health Plan | Longevity Health Founders, LLC | 892 | 77 | 1 | — | 11 | 2% |
| H2029 Humana | Humana Inc. | 0 | 77 | 1 | 0 | 11 | 2% |
| H4140 Doctors HealthCare Plans, Inc. | DOCTORS HEALTHCARE PLANS, INC. | 27,878 | 77 | 1 | 0 | 11 | 2% |
| H9589 Clear Spring Health | Group 1001 | — | 77 | 1 | −1 | 11 | 2% |
| S7694 Elixir Insurance | Rite Aid Corporation | — | 84 | 2 | −1 | 4 | 2% |
| H5991 EmblemHealth | EmblemHealth, Inc. | 2,285 | 78 | 1 | −1 | 10 | 3% |
| H5422 Anthem Blue Cross and Blue Shield | Elevance Health, Inc. | 14,085 | 78 | 1 | −1 | 10 | 3% |
| H2793 Imperial Insurance Companies, Inc | Imperial Health Plan of California | — | 78 | 1 | 0 | 10 | 3% |
| H9082 Molina Healthcare of New Mexico, Inc. | Molina Healthcare, Inc., | — | 78 | 1 | −1 | 10 | 3% |
| H7678 Molina Healthcare of Texas, Inc. | Molina Healthcare, Inc. | 2,963 | 78 | 2 | 0 | 10 | 3% |
| H7559 Molina Healthcare of Virginia | Molina Healthcare, Inc. | — | 78 | 1 | −2 | 10 | 3% |
History
| Star year | Code | Name | Measured | Weight | Source |
|---|---|---|---|---|---|
| 2027 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2025 – 12/31/2025 | 3 | Prescription Drug Events |
| 2026 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2024 – 12/31/2024 | 3 | Prescription Drug Events |
| 2025 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2023 – 12/31/2023 | 3 | Prescription Drug Events |
| 2024 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2022 – 12/31/2022 | 3 | Prescription Drug Events |
| 2023 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2021 – 12/31/2021 | 3 | Prescription Drug Events |
| 2022 | D10 | Medication Adherence for Cholesterol (Statins) | 01/01/2020 – 12/31/2020 | 3 | Prescription Drug Events |
| 2021 | D12 | Medication Adherence for Cholesterol (Statins) | 01/01/2019 – 12/31/2019 | 3 | Prescription Drug Events |
| 2020 | D12 | Medication Adherence for Cholesterol (Statins) | 01/01/2018 – 12/31/2018 | 3 | Prescription Drug Events |
| 2019 | D12 | Medication Adherence for Cholesterol (Statins) | 01/01/2017 – 12/31/2017 | 3 | Prescription Drug Events |
| 2018 | D13 | Medication Adherence for Cholesterol (Statins) | 01/01/2016 – 12/31/2016 | 3 | Prescription Drug Events |
| 2017 | D14 | Medication Adherence for Cholesterol (Statins) | 01/01/2015 - 12/31/2015 | 3 | Prescription Drug Events |
| 2016 | D14 | Medication Adherence for Cholesterol (Statins) | 01/01/2014 - 12/31/2014 | 3 | Prescription Drug Events |
| 2015 | D13 | Medication Adherence for Cholesterol (Statins) | 01/01/2013 - 12/31/2013 | 3 | Prescription Drug Events |